Near-Infrared Light-Activatable Microneedle System for Treating Superficial Tumors by Combination of Chemotherapy and Photothermal Therapy
Near-Infrared Light-Activatable Microneedle System for Treating Superficial Tumors by Combination of Chemotherapy and Photothermal Therapy
复制标题
DOI：
10.1021/acsnano.5b05043
复制
发表时间：
2016-01-01
期刊：
影响因子：
17.1
通讯作者：
Ling, Ming -Hung
中科院分区：
文献类型：
--
作者：
Chen, Mei-Chin;Lin, Zhi-Wei;Ling, Ming -Hung
由于癌症的侵袭性和复发性，经常需要重复和多模式治疗。传统的癌症疗法有严重的毒性和副作用的风险。因此，至关重要的是开发一种替代治疗方式，这种治疗方式是微创的，有效地治疗癌症，毒性低，并且可以根据需要重复。我们开发了一种光激活微针（MN）系统，可以重复和同时提供光热治疗和化疗浅表肿瘤，发挥协同抗癌作用。该系统由可嵌入的聚己内酯MN和可溶解的聚（乙烯醇）/聚乙烯吡咯烷酮支持阵列贴片组成，所述可嵌入的聚己内酯MN含有光敏纳米材料（六硼化镧）和抗癌药物（阿霉素; DOX）。由于这种支持阵列，MN可以完全插入皮肤并嵌入靶组织内，用于局部癌症治疗。当暴露在近红外光下时，嵌入的MN阵列均匀加热靶组织以诱导大的热消融区域，然后在50摄氏度熔化以在广泛的区域释放DOX，从而破坏肿瘤。这种光激活的加热和释放行为可以精确控制，并根据需要打开和关闭几个循环。我们证明MN介导的协同疗法在单次应用MN和三个周期的激光治疗后1周内完全根除4 T1肿瘤。没有观察到肿瘤复发和小鼠的显著体重减轻。因此，开发的具有独特可嵌入功能的光激活MN为需要长期和多种癌症治疗的患者提供了一种有效、用户友好且低毒性的选择。
Because of the aggressive and recurrent nature of cancers, repeated and multimodal treatments are often necessary. Traditional cancer therapies have a risk of serious toxicity and side effects. Hence, it is crucial to develop an alternative treatment modality that is minimally invasive, effectively treats cancers with low toxicity, and can be repeated as required. We developed a light-activatable microneedle (MN) system that can repeatedly and simultaneously provide photothermal therapy and chemotherapy to superficial tumors and exert synergistic anticancer effects. This system consists of embeddable polycaprolactone MNs containing a photosensitive nanomaterial (lanthanum hexaboride) and an anticancer drug (doxorubicin; DOX), and a dissolvable poly(vinyl alcohol)/polyvinylpyrrolidone supporting array patch. Because of this supporting array, the MNs can be completely inserted into the skin and embedded within the target tissue for locoregional cancer treatment. When exposed to near-infrared light, the embedded MN array uniformly heats the target tissue to induce a large thermal ablation area and then melts at 50 degrees C to release DOX in a broad area, thus destroying tumors. This light-activated heating and releasing behavior can be precisely controlled and switched on and off on demand for several cycles. We demonstrated that the MN-mediated synergistic therapy completely eradicated 4T1 tumors within 1 week after a single application of the MN and three cycles of laser treatment. No tumor recurrence and no significant body weight loss of mice were observed. Thus, the developed light-activatable MN with a unique embeddable feature offers an effective, user-friendly, and low-toxicity option for patients requiring long-term and multiple cancer treatments.